Latest Publications
HYTN Secures Additional Permits to Expand International GMP Cannabis Exports
HYTN Innovations Inc. is pleased to announce that it has received a new set of import permits from the United Kingdom’s Home Office and corresponding export permits from Health Canada.
HYTN Announces Initial Purchase Order under Manufacturing Partnership with Industry-Leading SNDL
HYTN Innovations Inc. is pleased to announce the receipt of an initial purchase order under manufacturing and pricing agreements (the Agreements) with SNDL Inc. (NASDAQ: SNDL) ("SNDL"), one of the world’s largest vertically integrated cannabis companies.
HYTN Announces Sale and Distribution of GMP Cannabis Products in the UK
HYTN is pleased to announce its successful export of cannabis to the United Kingdom’s 4C LABS. This announcement follows the news from November 28, 2024, that the Company received its first international order for products manufactured under its recently awarded Good Manufacturing Practices (GMP) designation.
HYTN Receives Opening Order and Import Permits from the UK's 4C Labs, Prepares Products for Export
HYTN is pleased to announce the receipt of initial orders and import permits from the UK's 4C Labs, marking a significant milestone in their partnership. This achievement allows HYTN to begin exporting premium cannabis-based pharmaceuticals to the UK under the company's recently established agreements.
HYTN Announces Marketing Program
HYTN is pleased to announce that it has engaged bullVestor Medien GmbH (“bullVestor”) to provide marketing services for an anticipated period of 6 months, or until budget exhaustion, commencing on November 15th, 2024, and provided that the term of the marketing services may be extended or shortened at the discretion of management.
HYTN Expands GMP Capabilities with New Licensed Activity
HYTN proudly announces that it has received an additional Good Manufacturing Practices (GMP) certification for its Kelowna manufacturing facility. This certification now includes distribution as a licenced activity under HYTN's Drug Establishment Licence (DEL) issued by Health Canada.
HYTN Files Business Acquisition Report
HYTN is pleased to announce, further to its news release dated July 19, 2024, that it has filed a Business Acquisition Report (BAR) in respect of its acquisition of Prism Scientific Labs Inc. The BAR may be found under the Company’s profile on SEDAR+ (www.sedarplus.ca).
HYTN Partners with the UK's 4C Labs, Validates GMP Certification
HYTN is proud to announce the establishment of international manufacturing and pricing agreements (the Agreements) with 4C LABS, a leading importer and distributor of cannabis-based pharmaceuticals in the United Kingdom.